Department of Pediatric Hematology, Children's Hospital of Orange County, 1201 W. La Veta Avenue, Orange, CA, 92868, USA.
Department of Pediatrics, University of California at Irvine, Orange, CA, USA.
J Clin Immunol. 2019 Jan;39(1):81-89. doi: 10.1007/s10875-018-0581-0. Epub 2019 Jan 3.
The association of immunodeficiency-related vaccine-derived rubella virus (iVDRV) with cutaneous and visceral granulomatous disease has been reported in patients with primary immunodeficiency disorders (PIDs). The majority of these PID patients with rubella-positive granulomas had DNA repair disorders. To support this line of inquiry, we provide additional descriptive data on seven previously reported patients with Nijmegen breakage syndrome (NBS) (n = 3) and ataxia telangiectasia (AT) (n = 4) as well as eight previously unreported patients with iVDRV-induced cutaneous granulomas and DNA repair disorders including NBS (n = 1), AT (n = 5), DNA ligase 4 deficiency (n = 1), and Artemis deficiency (n = 1). We also provide descriptive data on several previously unreported PID patients with iVDRV-induced cutaneous granulomas including cartilage hair hypoplasia (n = 1), warts, hypogammaglobulinemia, immunodeficiency, myelokathexis (WHIM) syndrome (n = 1), MHC class II deficiency (n = 1), Coronin-1A deficiency (n = 1), X-linked severe combined immunodeficiency (X-SCID) (n = 1), and combined immunodeficiency without a molecular diagnosis (n = 1). At the time of this report, the median age of the patients with skin granulomas and DNA repair disorders was 9 years (range 3-18). Cutaneous granulomas have been documented in all, while visceral granulomas were observed in six cases (40%). All patients had received rubella virus vaccine. The median duration of time elapsed from vaccination to the development of cutaneous granulomas was 48 months (range 2-152). Hematopoietic cell transplantation was reported to result in scarring resolution of cutaneous granulomas in two patients with NBS, one patient with AT, one patient with Artemis deficiency, one patient with DNA Ligase 4 deficiency, one patient with MHC class II deficiency, and one patient with combined immunodeficiency without a known molecular etiology. Of the previously reported and unreported cases, the majority share the diagnosis of a DNA repair disorder. Analysis of additional patients with this complication may clarify determinants of rubella pathogenesis, identify specific immune defects resulting in chronic infection, and may lead to defect-specific therapies.
免疫缺陷相关疫苗衍生风疹病毒(iVDRV)与原发性免疫缺陷病(PID)患者的皮肤和内脏肉芽肿性疾病有关。这些风疹病毒阳性肉芽肿的大多数 PID 患者均存在 DNA 修复障碍。为了支持这一研究方向,我们提供了 7 例先前报道的 Nijmegen 断裂综合征(NBS)(n=3)和共济失调毛细血管扩张症(AT)(n=4)患者以及 8 例先前未报道的 iVDRV 诱导的皮肤肉芽肿和 DNA 修复障碍患者的附加描述性数据,包括 NBS(n=1)、AT(n=5)、DNA 连接酶 4 缺乏症(n=1)和 Artemis 缺乏症(n=1)。我们还提供了数例先前未报道的 iVDRV 诱导的皮肤肉芽肿和 DNA 修复障碍患者的描述性数据,包括软骨毛发发育不良(n=1)、疣、低丙种球蛋白血症、免疫缺陷、骨髓病(WHIM)综合征(n=1)、MHC 类 II 缺乏症(n=1)、冠蛋白 1A 缺乏症(n=1)、X 连锁严重联合免疫缺陷(X-SCID)(n=1)和无分子诊断的联合免疫缺陷(n=1)。截至本报告发布时,患有皮肤肉芽肿和 DNA 修复障碍的患者的中位年龄为 9 岁(范围 3-18 岁)。所有患者均有皮肤肉芽肿的记录,6 例患者(40%)存在内脏肉芽肿。所有患者均接受过风疹病毒疫苗接种。从接种疫苗到皮肤肉芽肿形成的中位时间为 48 个月(范围 2-152)。有报道称,NBS 患者中的 2 例、AT 患者中的 1 例、Artemis 缺乏症患者中的 1 例、DNA 连接酶 4 缺乏症患者中的 1 例、MHC 类 II 缺乏症患者中的 1 例以及无已知分子病因的联合免疫缺陷患者中的 1 例接受造血细胞移植后皮肤肉芽肿的疤痕得到了缓解。在先前报道和未报道的病例中,大多数患者都存在 DNA 修复障碍的诊断。对这些并发症的其他患者进行分析可能会阐明风疹病毒发病机制的决定因素,确定导致慢性感染的特定免疫缺陷,并可能导致针对特定缺陷的治疗。